HAS Healthcare Advanced Synthesis (HAS, Formerly Helsinn Advanced Synthesis SA) Has Improved its ECOVADIS Sustainability Rating From Silver to Gold Status in One Year
The Swiss-based full-service contract development and manufacturing organization (CDMO) in the top 3% of all rated organizations in its category worldwide.
BIASCA, Switzerland, Sep. 7, 2022 /PRNewswire-PRWeb/ -- Biasca, Switzerland, September 1st, 2022 – HAS Healthcare Advanced Synthesis SA ("HAS"), a full-service contract development and manufacturing organization (CDMO) delivering high-quality, exclusive, personalized solutions to its healthcare clients, today announces that EcoVadis, the world's largest and most trusted provider of business sustainability ratings, creating a global network of more than 90,000+ rated companies, has awarded HAS a gold rating for 2022. The new gold rating places HAS in the top 6% of all the companies assessed worldwide, and in the top 3% in the category 'Manufacture of basic pharmaceutical products and pharmaceutical preparations' by EcoVadis.
EcoVadis rates companies in the four main topic areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.
Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis, commented: "We are delighted that our intensive efforts to become more sustainable over the years have been recognized by a global sustainability leader. Our gold rating is confirmation that sustainability is fully embedded in our business model. However, this is just one step further in our sustainability journey. We want to become one of the key leaders in our industry when it comes to sustainability." In 2021, HAS became Carbon Neutral, after a 10-year long effort to decarbonize its value chain.
About HAS Healthcare Advanced Synthesis (formerly Helsinn Advanced Synthesis SA)
HAS Healthcare Advanced Synthesis is a full-service CDMO committed to providing a reliable, first-class and tailor-made offering. The company develops and manufactures Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) and anticancer compounds for its clients from clinical to commercial supply, on an exclusive basis.
The production plant is located in Biasca, Switzerland and was established in 1984. The site is routinely inspected by the FDA, SwissMedic, and other global regulatory agencies.
Our wide range of reactors enable us to deliver a flexible batch size from grams to tens of tons, depending on your product needs. The HPAPI production suites are able to meet an OEL of 1 ug/m³ producing grams to hundreds of kgs per batch. The Anticancer facility has dedicated production suites with modern glovebox technology able to meet an OEL of 50 ng/m³ producing kgs up to 50 kg per batch.
Please visit our new website: https://www.hashealthcare.com
Media Contact
Sandra Moro, HAS Healthcare Advanced Synthesis, 41 (0) 91 873 94 30, [email protected]
SOURCE HAS Healthcare Advanced Synthesis
Share this article